Table 1 List of Lipid-PLGA nanoparticles and applications
From: Lipid-based surface engineering of PLGA nanoparticles for drug and gene delivery applications
Lipid | Polymeric core | Preparation method | Encapsulated Drug | Size(nm) | Charge(mV) | Application | Reference |
|---|---|---|---|---|---|---|---|
Lecithin/DSPE-PEG | PLGA | One step | Au/QDs | 50–60 | NA | Diagnostic/Optical imaging | [32] |
Chol | Curcumin | 203 | -0.67 ± 1.23 | Cancer therapy | [34] | ||
EPC, DOPE-Tf/TPGS | Aromatease Inhibitor | 150–190 | -18 ± 2 | Cancer therapy | [56] | ||
Lecithin, DMPE,DTPA/DSPE-PEG | Docetaxel, 90Y,111In | 65 | 35 | Cancer therapy | [57] | ||
Lecithin/DSPE-PEG | Paclitaxel - Gemcitabine | 70 ± 1 | -51 ± 2 | Cancer therapy | [58] | ||
Lecithin/DSPE-PEG | Paclitaxel | 55 ± 1 | NA | Treatment of coronary artery disease | [59] | ||
DSPE-PEG | docetaxel | 25 | -10 | Cancer therapy | [60] | ||
EPC DSPE-PEG | Two step | siRNA | 225 ± 8 | - 10 | Gene Delivery | [61] | |
FA-QLCS,Chol, PEG-OQLS | Paclitaxel | 184 ± 7 | 22 ± 4 | Targeted nanoparticle for cancer therapy | [62] | ||
Chol, DOTAP, DSPE-PEG | BSA | ~144 | +4–6 | Vaccine delivery | [63] | ||
DOPC,DOTAP, DSPE-PEG | One step | Sirolimus | 174 ± 9.6 | −14 ± 0.3 | Sustained antiproliferative therapy for the treatment of restenosis | [13] | |
Propolis | 183 ± 13.7 | −21 ± 2.08 | |||||
DOTAP | Sirolimus | 201 ± 10.3 | 36 ± 6.5 | ||||
Propolis | 205 ± 9.4 | 14 ± 4.1 | |||||
DOPC | Sirolimus | 201 ± 8.8 | −24 ± 1.2 | ||||
Propolis | 212 ± 11 | −32 ± 2.5 | |||||
DOPC,DOTAP | Sirolimus | 186 ± 8.6 | −12 ± 3.5 | ||||
Propolis | 194 ± 11.7 | −19 ± 2.4 | |||||
DOTAP (6 %) | One step | pDNA | 209 ± 10.4 | 36 ± 5.4 | Gene delivery | [15] | |
DOTAP (12 %) | 186 ± 7.9 | 49 ± 2.3 | |||||
DOTAP (18 %) | 163 ± 5.6 | 57 ± 2.5 | |||||
DOTAP (24 %) | 154 ± 5.2 | 64 ± 3.2 | |||||
RBC membranes | Two step | Doxorubicin | 70–90 | -10 ± 2.7 | Long circulating carrier | [44] | |
Platelet membranes | Docetaxel | 113.4 ± 1.2 | -29.5 ± 1.2 | Natural targeted drug delivery. Long circulating carrier | [26] | ||
Vancomycin | 200.3 ± 3.1 | -30.2 ± 1.0 | |||||
Cancer cell membranes | NA | ~110 | -35 ± 5 | Natural cancer targeted drug delivery. Whole cell cancer vaccine | [64] | ||
Monocyte membranes | Doxorubicin | ~150–180 | −16.5 | Natural cancer targeted drug delivery | [14] | ||
Adipose derived Stem cell membranes | VEGF | 100–150 | -15 ± 1.3 | Natural targeted drug delivery. Stem cell mimetic nanocarrier | [12] |